CYCLERION THERAPEUTICS, INC. Operating Cash Flow
CYCLERION THERAPEUTICS, INC. (CYCN) reported Operating Cash Flow of -$2.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- CYCLERION THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$1.43M.
- CYCLERION THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.18M.
- CYCLERION THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.58M, a 538.61% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$264.00K.
- CYCLERION THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$21.25M.
- CYCLERION THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$40.61M.
- CYCLERION THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2021 was -$36.52M.
- CYCLERION THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2020 was -$72.49M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.43M derived: 10-Q 6 month − S-4/A 3 month · filed 2026-08-04 | -$2.61M 10-Q · filed 2026-08-04 | -$4.19M derived: sum of 3 quarters · filed 2026-08-04 | -$4.45M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$1.18M S-4/A · filed 2026-07-22 | -$2.75M derived: sum of 2 quarters · filed 2026-07-22 | -$3.02M derived: sum of 3 quarters · filed 2026-07-22 | -$3.52M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$1.58M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-07-22 | -$1.84M derived: sum of 2 quarters · filed 2026-07-22 | -$2.35M derived: sum of 3 quarters · filed 2026-08-04 | -$3.31M S-4/A · filed 2026-07-22 |
| 2025-09-30 | -$264.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$767.00K derived: sum of 2 quarters · filed 2026-08-04 | -$1.74M 10-Q · filed 2025-11-12 | -$1.38M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$503.00K derived: 10-Q 6 month − S-4/A 3 month · filed 2026-08-04 | -$1.47M 10-Q · filed 2026-08-04 | -$1.11M derived: sum of 3 quarters · filed 2026-08-04 | -$2.83M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$968.00K S-4/A · filed 2026-07-22 | -$608.00K derived: sum of 2 quarters · filed 2026-07-22 | -$2.32M derived: sum of 3 quarters · filed 2026-07-22 | -$3.43M derived: sum of 4 quarters · filed 2026-07-22 |
| 2024-12-31 | $360.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-07-22 | -$1.36M derived: sum of 2 quarters · filed 2026-07-22 | -$2.46M derived: sum of 3 quarters · filed 2026-07-22 | -$4.33M S-4/A · filed 2026-07-22 |
| 2024-09-30 | -$1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.82M derived: sum of 2 quarters · filed 2025-11-12 | -$4.69M 10-Q · filed 2025-11-12 | -$6.23M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$2.98M 10-Q · filed 2025-08-05 | -$4.52M derived: sum of 3 quarters · filed 2025-11-12 | -$11.45M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-03-31 | -$1.87M 10-Q · filed 2025-05-06 | -$3.41M derived: sum of 2 quarters · filed 2025-11-12 | -$10.35M derived: sum of 3 quarters · filed 2025-11-12 | -$16.90M derived: sum of 4 quarters · filed 2025-11-12 |
| 2023-12-31 | -$1.54M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-12 | -$8.48M derived: sum of 2 quarters · filed 2025-11-12 | -$15.03M derived: sum of 3 quarters · filed 2025-11-12 | -$21.25M 10-K/A · filed 2025-11-12 |
| 2023-09-30 | -$6.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$13.49M derived: sum of 2 quarters · filed 2024-11-14 | -$19.70M 10-Q · filed 2024-11-14 | -$26.75M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$6.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$12.77M 10-Q · filed 2024-08-07 | -$19.81M derived: sum of 3 quarters · filed 2024-08-07 | -$29.73M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$6.21M 10-Q · filed 2024-05-07 | -$13.26M derived: sum of 2 quarters · filed 2024-05-07 | -$23.17M derived: sum of 3 quarters · filed 2024-05-07 | -$33.99M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$7.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$16.96M derived: sum of 2 quarters · filed 2024-03-05 | -$27.78M derived: sum of 3 quarters · filed 2024-03-05 | -$40.61M 10-K · filed 2024-03-05 |
| 2022-09-30 | -$9.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$20.73M derived: sum of 2 quarters · filed 2023-11-13 | -$33.57M 10-Q · filed 2023-11-13 | -$42.20M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$10.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | -$23.65M 10-Q · filed 2023-07-28 | -$32.28M derived: sum of 3 quarters · filed 2023-07-28 | -$40.21M derived: sum of 4 quarters · filed 2023-07-28 |
| 2022-03-31 | -$12.84M 10-Q · filed 2023-05-12 | -$21.46M derived: sum of 2 quarters · filed 2023-05-12 | -$29.39M derived: sum of 3 quarters · filed 2023-05-12 | -$34.90M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$8.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$16.55M derived: sum of 2 quarters · filed 2023-03-22 | -$22.06M derived: sum of 3 quarters · filed 2023-03-22 | -$36.52M 10-K · filed 2023-03-22 |
| 2021-09-30 | -$7.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$13.43M derived: sum of 2 quarters · filed 2022-11-03 | -$27.89M 10-Q · filed 2022-11-03 | -$41.93M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$5.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$19.96M 10-Q · filed 2022-08-09 | -$34.01M derived: sum of 3 quarters · filed 2022-08-09 | -$49.05M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$14.46M 10-Q · filed 2022-05-04 | -$28.50M derived: sum of 2 quarters · filed 2022-05-04 | -$43.54M derived: sum of 3 quarters · filed 2022-05-04 | -$57.77M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$14.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$29.09M derived: sum of 2 quarters · filed 2022-02-24 | -$43.31M derived: sum of 3 quarters · filed 2022-02-24 | -$72.49M 10-K · filed 2022-02-24 |
| 2020-09-30 | -$15.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$29.27M derived: sum of 2 quarters · filed 2021-11-09 | -$58.45M 10-Q · filed 2021-11-09 | -$80.61M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$14.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$43.40M 10-Q · filed 2021-07-29 | -$65.56M derived: sum of 3 quarters · filed 2021-07-29 | -$89.38M derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | -$29.18M 10-Q · filed 2021-04-30 | -$51.34M derived: sum of 2 quarters · filed 2021-04-30 | -$75.16M derived: sum of 3 quarters · filed 2021-04-30 | -$97.12M derived: sum of 4 quarters · filed 2021-04-30 |
| 2019-12-31 | -$22.16M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$45.98M derived: sum of 2 quarters · filed 2021-02-25 | -$67.94M derived: sum of 3 quarters · filed 2021-02-25 | -$102.22M 10-K · filed 2021-02-25 |
| 2019-09-30 | -$23.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$45.78M derived: sum of 2 quarters · filed 2020-11-05 | -$80.05M 10-Q · filed 2020-11-05 | -$103.20M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | -$21.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | -$56.24M 10-Q · filed 2020-08-03 | -$79.39M derived: sum of 3 quarters · filed 2020-08-03 | -$104.70M derived: sum of 4 quarters · filed 2020-08-03 |
| 2019-03-31 | -$34.27M 10-Q · filed 2020-05-04 | -$57.42M derived: sum of 2 quarters · filed 2020-05-04 | -$82.73M derived: sum of 3 quarters · filed 2020-05-04 | -$105.34M derived: sum of 4 quarters · filed 2020-05-04 |
| 2018-12-31 | -$23.15M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$48.46M derived: sum of 2 quarters · filed 2020-03-12 | -$71.07M derived: sum of 3 quarters · filed 2020-03-12 | -$97.50M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$25.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$47.92M derived: sum of 2 quarters · filed 2019-11-12 | -$74.35M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$22.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | -$49.05M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | -$26.43M 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |